Creso Pharma has an eye on North America with a new crop of cannabis-credentialed executives Creso Pharma Ltd has launched the next stage of its growth strategy, appointing executives with strong backgrounds in the lucrative cannabis market. In a push to strengthen its executive team, CPH has appointed William Lay as CEO and managing director, leading cannabis and psychedelics entrepreneur Bruce Linton as a non-executive director, and Micheline McKay as an executive director. CEO with growth ambition New CEO Lay was previously executive vice president overseeing strategy, origination, and operations at Creso Pharma. Lay is an experienced cannabis executive who began his career in banking, with roles across Canada and London for BMO Capital Markets. He then joined Canopy Growth Corp, rising to associate director of Mergers & Acquisitions in 2019, where he oversaw multiple transactions locally and internationally while progressing corporate strategy initiatives across the group. Over the last four years, Lay has managed and supported more than C$5 billion in cannabis M&A transactions, including leading the largest acquisition in the history of the cannabis sector.

Cannabis Law Report, 01/17/2022 18:16:00

Open article: